These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 9446321)

  • 21. [Prospects for antisense techniques].
    Zheng J; Tan T; Kuang A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 1999 Dec; 16(4):516-9, 523. PubMed ID: 12552736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transient suppression of transgene expression by means of antisense oligonucleotides: a method for the production of toxin-transducing recombinant viruses.
    Raykov Z; Legrand V; Homann HE; Rommelaere J
    Gene Ther; 2002 Mar; 9(5):358-62. PubMed ID: 11938456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nucleic acid-based modulation of cardiac gene expression for the treatment of cardiac diseases. Approaches and perspectives.
    Poller W; Fechner H; Kurreck J; Pauschinger M; Kühl U; Erdmann VA; Lamers JM; Schultheiss HP
    Z Kardiol; 2004 Mar; 93(3):171-93. PubMed ID: 15024585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Doxycycline-controlled splicing modulation by regulated antisense U7 snRNA expression cassettes.
    Marquis J; Kämpfer SS; Angehrn L; Schümperli D
    Gene Ther; 2009 Jan; 16(1):70-7. PubMed ID: 18701908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
    Kausch I; Böhle A
    Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of the androgen receptor by antisense oligonucleotides regulates the biological activity of androgens in SZ95 sebocytes.
    Fimmel S; Saborowski A; Térouanne B; Sultan C; Zouboulis CC
    Horm Metab Res; 2007 Feb; 39(2):149-56. PubMed ID: 17326011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific block of androgen receptor activity by antisense oligonucleotides.
    Hamy F; Brondani V; Spoerri R; Rigo S; Stamm C; Klimkait T
    Prostate Cancer Prostatic Dis; 2003; 6(1):27-33. PubMed ID: 12664061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tgf-beta antisense therapy increases angiogenic potential in human keratinocytes in vitro.
    Riedel K; Riedel F; Goessler UR; Germann G; Sauerbier M
    Arch Med Res; 2007 Jan; 38(1):45-51. PubMed ID: 17174722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modification of pre-mRNA processing: application to dystrophin expression.
    Wilton SD; Fletcher S
    Curr Opin Mol Ther; 2006 Apr; 8(2):130-5. PubMed ID: 16610765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel therapeutic targets along the Th17 pathway.
    Ouyang W; Filvaroff E; Hu Y; Grogan J
    Eur J Immunol; 2009 Mar; 39(3):670-5. PubMed ID: 19283720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sense and antisense oligonucleotides.
    Ross DW
    Arch Pathol Lab Med; 1990 Dec; 114(12):1296. PubMed ID: 2252431
    [No Abstract]   [Full Text] [Related]  

  • 34. Microencapsulated drug delivery: a new approach to pro-inflammatory cytokine inhibition.
    Oettinger CW; D'Souza MJ
    J Microencapsul; 2012; 29(5):455-62. PubMed ID: 22348221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Perspectives on practical use of biotechnologic advances, molecular biology and cellular engineering in clinical hematology].
    Ratajczak MZ
    Pol Arch Med Wewn; 1994 Nov; 92(5):373-9. PubMed ID: 7885984
    [No Abstract]   [Full Text] [Related]  

  • 36. [The use of antisense oligonucleotides for modulation of cytokine gene expression].
    Kozlov VA; Sennikov SV
    Vopr Med Khim; 1997; 43(5):308-20. PubMed ID: 9446321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunomodulation by cytokine antisense oligonucleotides.
    Lefebvre d'Hellencourt C; Diaw L; Guenounou M
    Eur Cytokine Netw; 1995; 6(1):7-19. PubMed ID: 7795178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of tracer accumulation in malignant tumors: gene expression, gene transfer, and phage display.
    Haberkorn U
    Curr Top Dev Biol; 2005; 70():145-69. PubMed ID: 16338341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytokines and therapeutic oligonucleotides.
    Hartmann G; Bidlingmaier M; Eigler A; Hacker U; Endres S
    Cytokines Cell Mol Ther; 1997 Dec; 3(4):247-56. PubMed ID: 9740353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.